中文别名:
莫扎伐坦;5-(二甲基氨基)-1-[4-(2-甲基苯甲酰胺基)苯甲酰]-2,3,4,5-四氢-1H-苯并氮杂卓;莫扎伐普坦;N-(4-(5-(二甲氨基)-2,3,4,5-四氢-1H-苯并[B]氮杂环庚烷-1-羰基)苯基)-2-甲基苯甲酰胺
英文别名:
OPC 31260;MOZAVAPTAN;5-(Dimethylamino)-1-[4-(2-methylbenzamido)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine;Benzamide, N-[4-[[5-(dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl]phenyl]-2-methyl-;-2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-carbonyl);N-(4-(5-(Dimethylamino);CS-134;OPC-31260; OPC31260L; OPC 31260
InChI:
InChI=1/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31)
密度:
1.21±0.1 g/cm3(Predicted)
沸点:
543.0±50.0 °C(Predicted)
产品用途:
莫扎伐普坦是非肽类V2受体拮抗剂,主要用于恶性肿瘤相关的抗利尿激素分泌不足综合征时的低钠血症罕见病。